

Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	C. freundii		C. koseri		K. aerogenes		E. cloacae		E. coli		K. oxytoca	
Amikacin	472	100%	151	100%	307	100%	730	100%	11782	100%	704	100%
Ampicillin	-	-	-	-	-	-	-	-	11782	68%	-	-
Ampicillin/Sul	-	-	151	99%	-	-	-	-	11766	73%	704	45%
Aztreonam	472	79%	151	99%	307	85%	730	76%	11782	95%	704	94%
Cefazolin	-	-	151	95%	-	-	-	-	11782	84%	704	33%
Cefepime	472	97%	151	100%	307	98%	793	~96%	11782	97%	704	97%
Cefoxitin	-	-	151	98%	-	-	-	-	11766	95%	704	96%
Ceftazidime	472	78%	151	99%	307	83%	730	74%	11782	95%	704	97%
Ceftaz/Avi	472	100%	151	100%	307	100%	730	99%	11766	100%	704	99%
Ceftol/Tazo	-	-	-	-	-	-	-	-	-	-	-	-
Ceftriaxone	472	77%	151	99%	307	83%	730	70%	11782	95%	704	94%
Cefuroxime	-	-	151	93%	307	74%	-	-	11766	93%	704	92%
Ciprofloxacin	472	90%	151	99%	307	97%	730	93%	11782	84%	704	95%
Ertapenem	472	97%	151	100%	307	96%	730	80%	11782	100%	704	99%
Gentamicin	472	97%	151	100%	307	99%	730	97%	11782	94%	704	98%
Imipenem	-	-	-	-	-	-	-	-	-	-	-	-
Levofloxacin	472	92%	151	100%	307	98%	730	96%	11782	88%	704	98%
Meropenem	472	100%	151	100%	307	99%	730	97%	11782	100%	704	100%
*Nitrofurantoin	427	91%	131	44%	236	17%	424	23%	11020	98%	550	90%
Piperac/Tazo	472	79%	151	97%	307	81%	730	73%	11782	98%	704	94%
Tetracycline	472	86%	151	99%	307	96%	730	90%	11766	84%	704	95%
Tigecycline	45	100%	20	100%	71	94%	313	96%	752	100%	154	100%
Tobramycin	472	98%	151	99%	307	99%	729	97%	11782	94%	704	97%
Trim/Sulfa	472	88%	151	100%	307	98%	730	91%	11782	86%	704	95%

~ SDD included in % Susceptible

* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

Low number of isolates. Results are less statistically valid.

ESBL incidence rate for 2023: 5.98%
 CRE incidence rate for 2023: 0.71%
 CP-CRE incidence rate for 2023: 0.15%

Reprints and additional information available at:

<http://home.nordx.mmc.org/depts/micro/docs/Index.htm>

Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	K. pneumoniae		M. morganii		P. mirabilis		P.aeruginosa		S.marcescens		Ac. baumannii	
Amikacin	2183	100%	205	100%	1195	100%	1034	100%	334	100%	43	95%
Ampicillin	-	-	-	-	1195	85%	-	-	-	-	-	-
Ampicillin/Sul	2179	80%	205	27%	1194	92%	-	-	-	-	43	100%
Aztreonam	2183	90%	205	99%	1195	99%	1034	85%	334	98%	-	-
Cefazolin	2183	82%	-	-	1195	2%	-	-	-	-	-	-
Cefepime	2183	91%	205	100%	1195	99%	1034	94%	334	99%	43	86%
Cefoxitin	2179	93%	205	73%	1194	97%	-	-	-	-	-	-
Ceftazidime	2183	90%	205	88%	1195	98%	1034	92%	334	99%	-	-
Ceftaz/Avi	2179	99%	205	100%	1194	100%	1033	99%	334	99%	-	-
Ceftol/Tazo	-	-	-	-	-	-	1034	99%	-	-	-	-
Ceftriaxone	2183	90%	205	95%	1195	97%	-	-	334	94%	43	56%
Cefuroxime	2179	86%	-	-	1194	95%	-	-	-	-	-	-
Ciprofloxacin	2183	86%	205	85%	1195	81%	1034	85%	334	95%	43	95%
Ertapenem	2183	98%	205	97%	1195	98%	-	-	334	96%	-	-
Gentamicin	2183	94%	205	95%	1195	93%	1034	98%	334	100%	43	91%
Imipenem	-	-	-	-	-	-	-	-	-	-	-	-
Levofloxacin	2183	90%	205	87%	1195	83%	1034	84%	334	97%	43	98%
Meropenem	2994	100%	205	98%	-	-	1034	95%	334	99%	43	100%
*Nitrofurantoin	1884	39%	-	-	-	-	-	-	-	-	-	-
Piperac/Tazo	2183	89%	205	98%	1195	99%	1034	89%	334	94%	-	-
Tetracycline	2179	83%	-	-	-	-	-	-	-	-	12	100%
Tigecycline	296	94%	-	-	-	-	-	-	172	98%	-	-
Tobramycin	2183	93%	205	97%	1195	92%	1034	99%	334	83%	43	95%
Trim/Sulfa	2183	86%	205	88%	1195	89%	-	-	-	-	43	95%

~ SDD included in % Susceptible

* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

Low number of isolates. Results are less statistically valid.

ESBL incidence rate for 2023: 5.98%
 CRE incidence rate for 2023: 0.71%
 CP-CRE incidence rate for 2023: 0.15%

Reprints and additional information available at:

<http://home.nordx.mmc.org/depts/micro/docs/Index.htm>

Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	E. faecalis		E. faecium		S. aureus		S. epidermidis		***MSSA***		***MRSA***	
Ampicillin	1759	100%	306	21%	-	-	-	-	-	-	-	-
Cefazolin	-	-	-	-	3681	71%	1246	54%	2856	98%	1118	2%
Ceftaroline	-	-	-	-	3674	99%	-	-	2855	100%	1112	97%
Clindamycin	-	-	-	-	3428	78%	723	64%	2637	82%	1063	67%
Daptomycin	1759	96%	342	~99%	3681	100%	1246	100%	2856	100%	1118	100%
Doxycycline	1759	36%	306	56%	3681	96%	1246	86%	2856	97%	1118	93%
Erythromycin	417	11%	86	10%	3375	54%	702	39%	2610	70%	1033	12%
Gentamicin	-	-	-	-	3681	98%	1159	100%	2856	99%	1118	97%
Levofloxacin	1345	85%	223	17%	3681	81%	1246	77%	2856	94%	1118	47%
Linezolid	1759	99%	306	97%	3681	100%	1246	100%	2856	100%	1118	100%
Minocycline	-	-	-	-	3369	97%	697	99%	2609	98%	1028	95%
Moxifloxacin	-	-	-	-	3375	82%	702	80%	2610	95%	1033	49%
*Nitrofurantoin	1345	100%	-	-	321	100%	545	100%	256	100%	92	100%
Oxacillin	-	-	-	-	3681	71%	1246	54%	2856	98%	1118	2%
Penicillin	-	-	-	-	-	-	-	-	-	-	-	-
Quinupr/Dalfo	-	-	91	63%	766	87%	-	-	583	87%	252	88%
#Rifampin	-	-	-	-	3681	99%	1246	99%	2856	100%	1118	99%
Tetracycline	1345	23%	223	14%	3681	90%	1244	80%	2856	91%	1118	85%
Tigecycline	393	100%	-	-	3369	99%	-	-	2609	100%	1028	96%
Trim/Sulfa	-	-	-	-	3678	89%	-	-	2856	93%	1115	79%
Vancomycin	1759	96%	306	36%	3681	100%	1246	100%	2856	100%	1118	100%
Gent Synergy	1759	87%	306	99%	-	-	-	-	-	-	-	-
Strep Synergy	1759	91%	306	52%	-	-	-	-	-	-	-	-

	H. influenzae		S. pneumoniae	
	# Tested	Suscep.	# Tested	Suscep.
Amoxicillin	-	-	187	98%
Ampicillin	15	87%	-	-
Amox/Clav	2	100%	-	-
Cefepime	-	-	187	98%
Cefotaxime	-	-	183	100%
Ceftriaxone	15	100%	184	100%
Clindamycin	-	-	187	81%
Erythromycin	-	-	187	58%
Levofloxacin	-	-	187	96%
Linezolid	-	-	187	100%
Meropenem	13	100%	187	91%
Moxifloxacin	-	-	187	99%
Penicillin	-	-	142	99%
Tetracycline	-	-	187	71%
Trim/Sulfa	2	100%	187	74%
Vancomycin	-	-	187	99%

~ SDD included in % Susceptible

* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

Rifampin should not be used alone for therapy.

Low number of isolates. Results are less statistically valid.

Routine testing of Haemophilus was discontinued in 2016. HI is tested from sterile sites or upon request.